Zhang W Y
Zhonghua Yi Xue Za Zhi. 1989 Apr;69(4):206-8, 16.
Serum levels of pregnancy specific beta 1 glycoprotein (SP1), human placental lactogen (hPL) and beta-human chorionic gonadotropin (beta-hCG) in the normal men, non-pregnant women, normal pregnant women and patients with trophoblastic diseases were determined by radioimmunoassay. Serum SP1, hPL and beta-hCG levels in patients with trophoblastic diseases decreased with advance of the degree of malignancy. The SP1/beta-hCG ratio was less than 1.5 in 4/36(11.1%) of the cases of hydatidiform mole, 13/16 (81.2%) of the cases of invasive mole and choriocarcinoma. The beta-hCG/hPL ratios were below 15 in 30/36 (83.3%) of the cases of hydatidiform mole and 4/16(25.5%) of the cases of malignant trophoblastic disease. After operation and chemotherapy, patients with SP1 and beta-hCG levels decreased gradually achieved favourable prognosis. Thus, this may be used as an index for monitoring and follow-up studies of trophoblastic disease.
采用放射免疫分析法测定正常男性、未孕女性、正常孕妇及滋养细胞疾病患者血清中妊娠特异性β1糖蛋白(SP1)、人胎盘催乳素(hPL)和β-人绒毛膜促性腺激素(β-hCG)的水平。滋养细胞疾病患者血清SP1、hPL和β-hCG水平随恶性程度进展而降低。葡萄胎病例中4/36(11.1%)、侵蚀性葡萄胎和绒毛膜癌病例中13/16(81.2%)的SP1/β-hCG比值小于1.5。葡萄胎病例中30/36(83.3%)、恶性滋养细胞疾病病例中4/16(25.5%)的β-hCG/hPL比值低于15。手术及化疗后,SP1和β-hCG水平逐渐下降的患者预后良好。因此,这可作为滋养细胞疾病监测和随访研究的指标。